Diabetes Camp Experience Associated With Improved Glycemia And Treatment Satisfaction

We compared glycemic metrics using continuous glucose monitoring (CGM) and quality of life between diabetes camp and the preceding home week. Insulin-treated youth (6-17 years) with T1D were enrolled at Barton Diabetes Camp and participated in 3 clinic visits: at the start of home week, where a Dexcom G6 CGM system was initialized; at the start of camp week, where the home week G6 was removed and a camp week G6 was inserted; and after camp, where the camp week G6 was removed. Problem areas in diabetes (PAID) surveys were administered at visits 2 and 3. Data from campers who did not complete all surveys were excluded. At camp, treatment decisions were informed by G6 as per FDA guidelines; interventions were prompted by daytime glucose levels ≤55 mg/dL or ≥350 mg/dL and for nighttime glucose levels ≤80 mg/dL or ≥300 mg/dL. Glycemic control and PAID scores were compared between home and camp weeks. Of 76 enrolled campers, 69 completed the study and 52 had results that qualified for analysis. Mean (SD) age was 12.5 (2.2) years. Most campers used insulin pumps (87.2%) and had experience with CGM (86.6%). Camp was associated with significant improvements in treatment satisfaction, time in range and in hyperglycemia, decreased basal insulin requirements, and improved insulin sensitivity (Table). Diabetes camp is associated with significant improvements in diabetes treatment satisfaction and glycemia compared to home care. Disclosure A. Darukhanavala: None. K.V. Dinunno: None. S. Puhr: Employee; Self; Dexcom, Inc. J.B. Welsh: Employee; Self; CSL Behring. L. Butler: None. D. Alfego: None. K.L. Magyar: None. Funding Dexcom, Inc.